As we continue our new products journey evaluating early stage agents in development with data at AACR23, it’s time to assess another batch of compounds in the context of the broader landscape.

What stands out and why does this or that agent matter?

Yes we all want to be able to tell the wood from the trees, but what are some of the critical questions needing to be asked and answered in order to be able to do this?

There’s a lot of intriguing and innovative drugs on the horizon at AACR23, so plenty to watch out for!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by